Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 63.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 164,523 shares of the company’s stock after selling 286,198 shares during the quarter. Jane Street Group LLC owned 0.08% of Allogene Therapeutics worth $350,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cibc World Markets Corp acquired a new position in Allogene Therapeutics in the 4th quarter worth about $26,000. PAX Financial Group LLC purchased a new stake in Allogene Therapeutics during the 4th quarter worth approximately $27,000. RPO LLC purchased a new stake in Allogene Therapeutics during the 4th quarter worth approximately $31,000. Syon Capital LLC purchased a new stake in Allogene Therapeutics during the 4th quarter worth approximately $39,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Allogene Therapeutics during the 4th quarter worth approximately $43,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock opened at $1.17 on Monday. The firm has a market capitalization of $254.82 million, a price-to-earnings ratio of -0.75 and a beta of 0.60. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $3.78. The stock has a 50 day moving average of $1.35 and a 200 day moving average of $1.78.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). Analysts forecast that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Insider Buying and Selling

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at $10,342,075.24. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 61,757 shares of company stock worth $115,873. Company insiders own 13.20% of the company’s stock.

Analyst Upgrades and Downgrades

ALLO has been the subject of several research reports. HC Wainwright cut their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Truist Financial cut their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Citizens Jmp lowered Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citigroup cut their price objective on Allogene Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).